• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Anyone Ready to Oxytocin + ALK%i?

alk5i

  • Please log in to reply
33 replies to this topic

#31 sub7

  • Topic Starter
  • Guest
  • 256 posts
  • 16

Posted 29 October 2020 - 10:24 AM

 

The following patent should be studied. .....

 
Patent number: 10265372 "Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues"  - rejuvenation of tissues by oxytocin together with an ALK5 antagonist. 

 

 

Here is the patent
https://patents.just...patent/10265372

 

The amount of the OXTR agonist for the contacting step, e.g., for administering to a subject may be in the range of 7.5 nM-30 nM and the amount of the ALK5 antagonist may be in the range of 0.05 μM-3 μM. The ratio of OXTR agonist to the ALK5 antagonist used for contacting step, e.g., for administering to a subject as disclosed herein may be 1:50, 50:1, 1:40, 40:1, 1:30, 30:1, 1:25, 25:1, 1:10, 10:1, 1:5, 5:1, or 1:1.

 

Now, as with most most patent papers, the above link is a jumbled mess and offers little in the way of actionable information.

 

If we are unable to inject as much Oxytocin as would be required for this exact experiment, how about maximizing the circulating dose of Oxytocin through Trenbolone and Estrogen (or Estradiol) injections:

 

:text=oxytocin%20in%20cattle-,Chronic%20exposure%20to%20anabolic%20steroids%20induces%20the%20muscle%20expression%20of,Physiol%20Genomics' class='bbc_url' title='External link' rel='nofollow external'>https://pubmed.ncbi....hysiol Genomics.

 

Chronic exposure to anabolic steroids induces the muscle expression of oxytocin and a more than fiftyfold increase in circulating oxytocin in cattle

 

"...We also observed an ∼50-fold higher level of circulating oxytocin in the plasma of treated animals at the time of biopsy. "

 

A mere 20 days of exposure to Trenbolone and Estrogen resulted in the above results and for a human they are totally doable. Bodybuilding enthusiasts do much, much longer cycles of Trenbolone.

 

-------------------------------------------------------

The other issue that remains to be resolved is whether the ALK5i dose is tolerable. As far as I know, a number of human studies with ALK5i have been done and we do have some idea about how much can be used without severe side effects. If the ALK5i dose mentioned above is doable, enhancing Oxytocin through those anabolic hormones remains the most viable route -at least, as far as I can see. 


  • like x 1

#32 sub7

  • Topic Starter
  • Guest
  • 256 posts
  • 16

Posted 01 November 2020 - 12:17 PM

OK, reviving this thread again

As per this link:
https://pubchem.ncbi...mpound/Oxytocin

Molecular Weight of Oxytocin = 1007.2 g/mol
for a quick calculation let us just use 1000 gram per mole as opposed to the more precıse 1007.2 (an error of less than 1%).
 
That results in 1 microgram = 1 nanomole and if that is the case, the above
The amount of the OXTR agonist for the contacting step, e.g., for administering to a subject may be in the range of 7.5 nM-30 nM
would come out to a very doable dosage.
 
We would need at most 30 micrograms.
 
In Post 30 on the previous page RWhigham pointed out that 
1 mg /(1.68 ug/iu) = 595 iu
 
and 30 micrograms makes under 18 iu -a very easily injectable dose.
Is there an an error somewhere -in my calculations or in my interpretation of the patent from which I quoted the bolded part.

Edited by sub7, 01 November 2020 - 12:20 PM.


sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#33 RWhigham

  • Member
  • 485 posts
  • 457
  • Location:United States
  • NO

Posted 01 November 2020 - 07:29 PM

The above quote from the patent appears to say the required dose is 7.5-30 nM (independent of critter). This does not agree with the discussion of doses specified for mice and humans (given later). I think they may have meant a concentration of 7.5-30 nM. (It's conventional to omit the per liter when specifying a molar concentration, so this is 7.5-30 nM/L). But using this to compute a dose is hopeless. We don't know where the 7.5-30 nM concentration has to occur--perhaps this applies to an in-vitro medium or inside of in-vitro cells?

 

Example: A 60kg human has about 5 L of blood, 10 L of not blood extracellular fluid, and 25 L of intracellular fluid, (40 L total). A 7.5-30 nM concentration in 10 L of extracellular fluid tales a dose of at least 10 L x 7.5-30 nM assuming the oxytocin leaves the blood but does not enter the cells (neither assumption is justified). On top of that the cells need to remain bathed in at least this concentration or for 5 days.

 

Reality

The mouse dose specified later in the patent is 0.01 to 1 ug/g. = 0.01 to 1 mg/kg.  For a 60 kg human this is 0.6 to 60 mg/human-day. The patent says the mouse HED might be used. Applying the mouse HED of 1/12  gives 0.05 to 5 mg/human-day. The successful mouse experiment used the larger dose of 1ug/g. So to replicate that success would suggest a dose of 5 mg/human-day (for a 60kg human).


Edited by RWhigham, 01 November 2020 - 08:24 PM.

  • Informative x 1

sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#34 sub7

  • Topic Starter
  • Guest
  • 256 posts
  • 16

Posted 02 November 2020 - 09:41 AM

RWhigham,

 

Very likely you are correct. So where do we go from here?

As mentioned below, we can try to add some anabolic steroids for a while in addition to injecting Oxytocin. An additional step that can be taken is to also consume yogurt cultured with the L.Reuteri 6475 strain, which -as discussed extensively on this forum- can also boost Oxytocin significantly. We can only hope that the sum total of these 3 will elevate Oxytocin to a helpful level. It may or may not.

 

The question then becomes -if we were to assume for a moment that the aforementioned interventions will provide sufficient support on the Oxytocin side of things- whether we can somewhat safely inject the ALK5i dose that would be required. Any idea?






1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users